Both Kirin and GN Corporation have recently announced new COVID-19 research endeavours using their existing health supplements.
For GN Corporation, it showed that intake of its beta-glucan products could reduce inflammatory biomarkers in COVID-19 patients compared to just the standard treatment alone.
This is according to its trial conducted in India and involved 40 patients with mild to moderate COVID-19.
Kirin, on the other hand, is assessing if Lactococcus lactis Strain Plasma – which it has been researching since 2010, could alleviate mild COVID-19 symptoms.
The strain has been found to activate plasma cytoid dendritic cells (pDCs), also known as the command center of the immune system responsible for the defense against viral infections.
The 14-day trial will be jointly conducted with Nagasaki University.
Lastly, MGC Pharmaceuticals said in January that it has received an import approval from the Food Safety and Standards Authority of India (FSSAI) for its proprietary food supplement ArtemiC Rescue.
The product, which contains artemisinin, curcumin, Boswellia serrata, and vitamin C, has been proven in a phase II clinical trial involving 50 patients in India and Israel in 2020.
According to the trial results, none in the intervention group required additional oxygen, mechanical ventilation or admission to the ICU, but all of these events were reported in the placebo group.
The company has also embarked on another clinical trial to test out the formula’s effect in alleviating symptoms of long COVID syndrome.
Listen to the podcast to find out more.
